A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ADU-1604, an Anti-CTLA-4 Antibody, in Adults With Metastatic Melanoma
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 May 2019
Price : $35 *
At a glance
- Drugs ADU-1604 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; First in man
- Sponsors Aduro BioTech
- 02 May 2019 Planned End Date changed from 18 Sep 2020 to 1 Sep 2019.
- 02 May 2019 Planned primary completion date changed from 29 May 2020 to 1 Aug 2019.
- 02 May 2019 Status changed from recruiting to active, no longer recruiting.